Ligand Pharmaceuticals LGND Income from financial royalty assets — Total revenues and income
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's income from financial royalty assets — total revenues and income.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's income from financial royalty assets — total revenues and income?
- Ligand Pharmaceuticals (LGND) reported income from financial royalty assets — total revenues and income of $10.03M in Q1 2026.
- How has Ligand Pharmaceuticals's income from financial royalty assets — total revenues and income changed year-over-year?
- Ligand Pharmaceuticals's income from financial royalty assets — total revenues and income increased by 69.9% year-over-year, from $5.9M to $10.03M.
- What is the long-term trend for Ligand Pharmaceuticals's income from financial royalty assets — total revenues and income?
- Over 3 years (2022 to 2025), Ligand Pharmaceuticals's income from financial royalty assets — total revenues and income has grown at a 319.7% compound annual growth rate (CAGR), from $385K to $28.47M.
- What does income from financial royalty assets — total revenues and income mean?
- This metric represents the total gross revenue and other income generated specifically from the company's portfolio of financial royalty assets. It captures the cash inflows derived from contractual rights to future product sales or milestone payments associated with licensed drug technologies. This figure serves as a key indicator of the commercial success and monetization velocity of the company's royalty-based business model.